$6.27
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2013-10-21. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Country

US

CEO

Mr. John Duke

IPO date

2013

Employees

316

ISIN

US4169062043

Key stats

Open

$6.27

Volume

11.29K

Market cap

$28.10M

Prev. close

$6.23

Impl / hst vl

-

Open interest

$0.00

$6.27

Day’s Range

$6.27

$0.40

52W Range

$7.50

Valuation

61
Valuation score
Undervalued
P/E
-
P/S
0.34
P/B
2.88
Current ratio
1.99
Debt / Equity
2.90
ROE
-73.04%
Gross margin
58.99%
Income growth
20.27%
FCF growth
84.46

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$6.12
The top 3 analysts forecasts that 12-month price may decrease by 2.39%, with a low of $6.06 and a high of $6.30
$6.06
Low
$6.12
Avg
$6.30
High
Current price

Earnings

Q1 ‘26 revenue
$20.76M
Q1 ‘26 net income
-$3.42M
Revenue
Net income
Previous EPS
-$0.33
Estimate EPS
-$0.43
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply